Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors

Summary

The purpose of this multi-center, open-label, escalating dose study is to assess the safety and tolerability of PPI-2458 in subjects with Non-Hodgkin's Lymphoma (NHL)and solid tumors. Subjects will be treated every other day (QOD) with PPI-2458 while being monitored closely for adverse events.

Timeline

Start

2004-12

Primary completion

—

Completion

2007-07

Outcome

Outcome not reported

Stopped: “terminated due to corporate transaction.”

Drugs

Indications